|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:USP18-DAPK2 (FusionGDB2 ID:97251) |
Fusion Gene Summary for USP18-DAPK2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: USP18-DAPK2 | Fusion gene ID: 97251 | Hgene | Tgene | Gene symbol | USP18 | DAPK2 | Gene ID | 11274 | 23604 |
| Gene name | ubiquitin specific peptidase 18 | death associated protein kinase 2 | |
| Synonyms | ISG43|PTORCH2|UBP43 | DRP-1|DRP1 | |
| Cytomap | 22q11.21 | 15q22.31 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ubl carboxyl-terminal hydrolase 1843 kDa ISG15-specific proteaseISG15-specific-processing proteasehUBP43ubiquitin specific protease 18ubl thioesterase 18ubl thiolesterase 18 | death-associated protein kinase 2DAP kinase 2DAP-kinase-related protein 1 beta isoform | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | Q9UIK4 | |
| Ensembl transtripts involved in fusion gene | ENST00000215794, | ENST00000558482, ENST00000261891, ENST00000457488, ENST00000558069, | |
| Fusion gene scores | * DoF score | 5 X 6 X 4=120 | 8 X 9 X 8=576 |
| # samples | 5 | 13 | |
| ** MAII score | log2(5/120*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(13/576*10)=-2.14755718841386 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: USP18 [Title/Abstract] AND DAPK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | USP18(18643035)-DAPK2(64275953), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | DAPK2 | GO:0006468 | protein phosphorylation | 10376525 |
| Tgene | DAPK2 | GO:0035556 | intracellular signal transduction | 10376525 |
| Fusion gene breakpoints across USP18 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across DAPK2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | LIHC | TCGA-DD-A73F-01A | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - |
Top |
Fusion Gene ORF analysis for USP18-DAPK2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-5UTR | ENST00000215794 | ENST00000558482 | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - |
| In-frame | ENST00000215794 | ENST00000261891 | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - |
| In-frame | ENST00000215794 | ENST00000457488 | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - |
| In-frame | ENST00000215794 | ENST00000558069 | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000215794 | USP18 | chr22 | 18643035 | + | ENST00000261891 | DAPK2 | chr15 | 64275953 | - | 3189 | 684 | 430 | 1704 | 424 |
| ENST00000215794 | USP18 | chr22 | 18643035 | + | ENST00000457488 | DAPK2 | chr15 | 64275953 | - | 2302 | 684 | 430 | 1704 | 424 |
| ENST00000215794 | USP18 | chr22 | 18643035 | + | ENST00000558069 | DAPK2 | chr15 | 64275953 | - | 2059 | 684 | 430 | 2058 | 543 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000215794 | ENST00000261891 | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - | 0.001369883 | 0.99863017 |
| ENST00000215794 | ENST00000457488 | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - | 0.002695615 | 0.9973043 |
| ENST00000215794 | ENST00000558069 | USP18 | chr22 | 18643035 | + | DAPK2 | chr15 | 64275953 | - | 0.006193789 | 0.99380624 |
Top |
Fusion Genomic Features for USP18-DAPK2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for USP18-DAPK2 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:18643035/chr15:64275953) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | DAPK2 |
| FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell death signals, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Acts as a mediator of anoikis and a suppressor of beta-catenin-dependent anchorage-independent growth of malignant epithelial cells. May play a role in granulocytic maturation (PubMed:17347302). Regulates granulocytic motility by controlling cell spreading and polarization (PubMed:24163421). {ECO:0000269|PubMed:17347302, ECO:0000269|PubMed:24163421, ECO:0000269|PubMed:26047703}.; FUNCTION: Isoform 2 is not regulated by calmodulin. It can phosphorylate MYL9. It can induce membrane blebbing and autophagic cell death. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000261891 | 0 | 11 | 29_37 | 30 | 371.0 | Nucleotide binding | ATP | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000457488 | 1 | 12 | 29_37 | 30 | 371.0 | Nucleotide binding | ATP | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000558069 | 1 | 10 | 29_37 | 30 | 489.0 | Nucleotide binding | ATP | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000261891 | 0 | 11 | 277_344 | 30 | 371.0 | Region | Note=Calmodulin-binding | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000261891 | 0 | 11 | 292_301 | 30 | 371.0 | Region | Autoinhibitory domain | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000457488 | 1 | 12 | 277_344 | 30 | 371.0 | Region | Note=Calmodulin-binding | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000457488 | 1 | 12 | 292_301 | 30 | 371.0 | Region | Autoinhibitory domain | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000558069 | 1 | 10 | 277_344 | 30 | 489.0 | Region | Note=Calmodulin-binding | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000558069 | 1 | 10 | 292_301 | 30 | 489.0 | Region | Autoinhibitory domain |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | USP18 | chr22:18643035 | chr15:64275953 | ENST00000215794 | + | 3 | 11 | 55_370 | 84 | 373.0 | Domain | Note=USP |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000261891 | 0 | 11 | 23_285 | 30 | 371.0 | Domain | Protein kinase | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000457488 | 1 | 12 | 23_285 | 30 | 371.0 | Domain | Protein kinase | |
| Tgene | DAPK2 | chr22:18643035 | chr15:64275953 | ENST00000558069 | 1 | 10 | 23_285 | 30 | 489.0 | Domain | Protein kinase |
Top |
Fusion Gene Sequence for USP18-DAPK2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >97251_97251_1_USP18-DAPK2_USP18_chr22_18643035_ENST00000215794_DAPK2_chr15_64275953_ENST00000261891_length(transcript)=3189nt_BP=684nt GACAGAATGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAGCGAGGGCTGGAAGTCTGGAGCAGGTGCGCGGCTGCAACGGCAGCC GCGGGAAGCTCGGGCCGGCAGGGTTTCCCCGCACGCTGGCGCCCAGCTCCCGGCGCGGAGGCCGCTGTAAGTTTCGCTTTCCATTCAGTG GAAAACGAAAGCTGGGCGGGGTGCCACGAGCGCGGGGCCAGACCAAGGCGGGCCCGGAGCGGAACTTCGGTCCCAGCTCGGTCCCCGGCT CAGTCCCGACGTGGAACTCAGCAGCGGAGGCTGGACGCTTGCATGGCGCTTGAGAGATTCCATCGTGCCTGGCTCACATAAGCGCTTCCT GGAAGTGAAGTCGTGCTGTCCTGAACGCGGGCCAGGCAGCTGCGGCCTGGGGGTTTTGGAGTGATCACGAATGAGCAAGGCGTTTGGGCT CCTGAGGCAAATCTGTCAGTCCATCCTGGCTGAGTCCTCGCAGTCCCCGGCAGATCTTGAAGAAAAGAAGGAAGAAGACAGCAACATGAA GAGAGAGCAGCCCAGAGAGCGTCCCAGGGCCTGGGACTACCCTCATGGCCTGGTTGGTTTACACAACATTGGACAGACCTGCTGCCTTAA CTCCTTGATTCAGGTGTTCGTAATGAATGTGGACTTCACCAGGATATTGAAGAGTGGCCAGTTTGCCATCGTGAAGAAGTGCCGGGAGAA GAGCACGGGGCTTGAGTATGCAGCCAAGTTCATCAAGAAGCGGCAGAGCCGGGCGAGCCGGCGCGGTGTGAGCCGGGAGGAGATCGAGCG GGAGGTGAGCATCCTGCGGCAGGTGCTGCACCACAATGTCATCACGCTGCACGACGTCTATGAGAACCGCACCGACGTGGTGCTCATCCT TGAGCTAGTGTCTGGAGGAGAGCTCTTCGATTTCCTGGCCCAGAAGGAGTCACTGAGTGAGGAGGAGGCCACCAGCTTCATTAAGCAGAT CCTGGATGGGGTGAACTACCTTCACACAAAGAAAATTGCTCACTTTGATCTCAAGCCAGAAAACATTATGTTGTTAGACAAGAATATTCC CATTCCACACATCAAGCTGATTGACTTTGGTCTGGCTCACGAAATAGAAGATGGAGTTGAATTTAAGAATATTTTTGGGACGCCGGAATT TGTTGCTCCAGAAATTGTGAACTACGAGCCCCTGGGTCTGGAGGCTGACATGTGGAGCATAGGCGTCATCACCTACATCCTCTTAAGTGG AGCATCCCCTTTCCTGGGAGACACGAAGCAGGAAACACTGGCAAATATCACAGCAGTGAGTTACGACTTTGATGAGGAATTCTTCAGCCA GACGAGCGAGCTGGCCAAGGACTTTATTCGGAAGCTTCTGGTTAAAGAGACCCGGAAACGGCTCACAATCCAAGAGGCTCTCAGACACCC CTGGATCACGCCGGTGGACAACCAGCAAGCCATGGTGCGCAGGGAGTCTGTGGTCAATCTGGAGAACTTCAGGAAGCAGTATGTCCGCAG GCGGTGGAAGCTTTCCTTCAGCATCGTGTCCCTGTGCAACCACCTCACCCGCTCGCTGATGAAGAAGGTGCACCTGAGGCCGGATGAGGA CCTGAGGAACTGTGAGAGTGACACTGAGGAGGACATCGCCAGGAGGAAAGCCCTCCACCCACGGAGGAGGAGCAGCACCTCCTAACTGGC CTGACCTGCAGTGGCCGCCAGGGAGGTCTGGGCCCAGCGGGGCTCCCTTCTGTGCAGACTTTTGGACCCAGCTCAGCACCAGCACCCGGG CGTCCTGAGCACTTTGCAAGAGAGATGGGCCCAAGGAATTCAGAAGAGCTTGCAGGCAAGCCAGGAGACCCTGGGAGCTGTGGCTGTCTT CTGTGGAGGAGGCTCCAGCATTCCCAAAGCTCTTAATTCTCCATAAAATGGGCTTTCCTCTGTCTGCCATCCTCAGAGTCTGGGGTGGGA GTGTGGACTTAGGAAAACAATATAAAGGACATCCTCATCATCACGGGGTGAAGGTCAGACTAAGGCAGCCTTCTTCACAGGCTGAGGGGG TTCAGAACCAGCCTGGCCAAAAATTACACCAGAGAGACAGAGTCCTCCCCATTGGGAACAGGGTGATTGAGGAAAGTGAACCTTGGGTGT GAGGGACCAATCCTGTGACCTCCCAGAACCATGGAAGCCAGGACGTCAGGCTGACCAACACCTCAGACCTTCTGAAGCAGCCCATTGCTG GCCCGCCATGTTGTAATTTTGCTCATTTTTATTAAACTTCTGGTTTACCTGATGCTTGGCTTCTTTTAGGGCTACCCCCATCTCATTTCC TTTAGCCCGTGTGCCTGTAACTCTGAGGGGGGGCACCCAGTGGGGTGCTGAGTGGGCAGAATCTCAGAAGGTCCTCCTGAACCGTCCGCG CAGGCCTGCAGTGGGCCTGCCTCCTCCTTGCTTCCCTAACAGGAAGGTGTCCAGTTCAAGAGAACCCACCCAGAGACTGGGAGTGGTGGC TCACGCCTATAATCCCTGCGCTTTGGCAGTCCGAGGCAGGGGAATTGCTTGAACTCAGGAGTTGGAGACCAGCCTGGGCAACATGGCAAA ACGCAGTCTGTACAAAAAATACAAAAAATTAGCCAGGTGTAGGGGTAGGCACCTGGCATCCCAGCTACTCCAGGGGCTGAGGTGACAGCA TTGCTTAAGCCCAGAAGGTCGAGGCTGCAGTGAGCTGAGATCACGCCACTGCACTCCAGTCTGGGTGACAGAGAGAGACCATATCCAAAA AAAAAAAAAGTTGCCAGAGACGAGTATGCCCATGCTCCCTCTACCTCACTGCCACCACTCCTGCTGTTAGGAGCTGAGTGTGTCTCCCTA AAATTTCTATGTTGAAGTCTTAACCCTTGGTACCACAGAATATCACTGTATTTGGAGATGGGGTCTTTAGAAAGGCACTTAAATTAAAAT GAGCTCACTGATATGGGCCCCGATGCAATATAATTGGTGTCCTTATAAGAAGGGGAGGTTAGGACACGCAGGAAAGACCACATGAAGGCC CAGGAGTGGGAGGGGGAATAGCCATCGACAAACTAAGGGGGCCTCAGAGGAAACCAACCCTGCTGACACCTCAATCTTAGACTCTGGCCT >97251_97251_1_USP18-DAPK2_USP18_chr22_18643035_ENST00000215794_DAPK2_chr15_64275953_ENST00000261891_length(amino acids)=424AA_BP=84 MSKAFGLLRQICQSILAESSQSPADLEEKKEEDSNMKREQPRERPRAWDYPHGLVGLHNIGQTCCLNSLIQVFVMNVDFTRILKSGQFAI VKKCREKSTGLEYAAKFIKKRQSRASRRGVSREEIEREVSILRQVLHHNVITLHDVYENRTDVVLILELVSGGELFDFLAQKESLSEEEA TSFIKQILDGVNYLHTKKIAHFDLKPENIMLLDKNIPIPHIKLIDFGLAHEIEDGVEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVI TYILLSGASPFLGDTKQETLANITAVSYDFDEEFFSQTSELAKDFIRKLLVKETRKRLTIQEALRHPWITPVDNQQAMVRRESVVNLENF -------------------------------------------------------------- >97251_97251_2_USP18-DAPK2_USP18_chr22_18643035_ENST00000215794_DAPK2_chr15_64275953_ENST00000457488_length(transcript)=2302nt_BP=684nt GACAGAATGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAGCGAGGGCTGGAAGTCTGGAGCAGGTGCGCGGCTGCAACGGCAGCC GCGGGAAGCTCGGGCCGGCAGGGTTTCCCCGCACGCTGGCGCCCAGCTCCCGGCGCGGAGGCCGCTGTAAGTTTCGCTTTCCATTCAGTG GAAAACGAAAGCTGGGCGGGGTGCCACGAGCGCGGGGCCAGACCAAGGCGGGCCCGGAGCGGAACTTCGGTCCCAGCTCGGTCCCCGGCT CAGTCCCGACGTGGAACTCAGCAGCGGAGGCTGGACGCTTGCATGGCGCTTGAGAGATTCCATCGTGCCTGGCTCACATAAGCGCTTCCT GGAAGTGAAGTCGTGCTGTCCTGAACGCGGGCCAGGCAGCTGCGGCCTGGGGGTTTTGGAGTGATCACGAATGAGCAAGGCGTTTGGGCT CCTGAGGCAAATCTGTCAGTCCATCCTGGCTGAGTCCTCGCAGTCCCCGGCAGATCTTGAAGAAAAGAAGGAAGAAGACAGCAACATGAA GAGAGAGCAGCCCAGAGAGCGTCCCAGGGCCTGGGACTACCCTCATGGCCTGGTTGGTTTACACAACATTGGACAGACCTGCTGCCTTAA CTCCTTGATTCAGGTGTTCGTAATGAATGTGGACTTCACCAGGATATTGAAGAGTGGCCAGTTTGCCATCGTGAAGAAGTGCCGGGAGAA GAGCACGGGGCTTGAGTATGCAGCCAAGTTCATCAAGAAGCGGCAGAGCCGGGCGAGCCGGCGCGGTGTGAGCCGGGAGGAGATCGAGCG GGAGGTGAGCATCCTGCGGCAGGTGCTGCACCACAATGTCATCACGCTGCACGACGTCTATGAGAACCGCACCGACGTGGTGCTCATCCT TGAGCTAGTGTCTGGAGGAGAGCTCTTCGATTTCCTGGCCCAGAAGGAGTCACTGAGTGAGGAGGAGGCCACCAGCTTCATTAAGCAGAT CCTGGATGGGGTGAACTACCTTCACACAAAGAAAATTGCTCACTTTGATCTCAAGCCAGAAAACATTATGTTGTTAGACAAGAATATTCC CATTCCACACATCAAGCTGATTGACTTTGGTCTGGCTCACGAAATAGAAGATGGAGTTGAATTTAAGAATATTTTTGGGACGCCGGAATT TGTTGCTCCAGAAATTGTGAACTACGAGCCCCTGGGTCTGGAGGCTGACATGTGGAGCATAGGCGTCATCACCTACATCCTCTTAAGTGG AGCATCCCCTTTCCTGGGAGACACGAAGCAGGAAACACTGGCAAATATCACAGCAGTGAGTTACGACTTTGATGAGGAATTCTTCAGCCA GACGAGCGAGCTGGCCAAGGACTTTATTCGGAAGCTTCTGGTTAAAGAGACCCGGAAACGGCTCACAATCCAAGAGGCTCTCAGACACCC CTGGATCACGCCGGTGGACAACCAGCAAGCCATGGTGCGCAGGGAGTCTGTGGTCAATCTGGAGAACTTCAGGAAGCAGTATGTCCGCAG GCGGTGGAAGCTTTCCTTCAGCATCGTGTCCCTGTGCAACCACCTCACCCGCTCGCTGATGAAGAAGGTGCACCTGAGGCCGGATGAGGA CCTGAGGAACTGTGAGAGTGACACTGAGGAGGACATCGCCAGGAGGAAAGCCCTCCACCCACGGAGGAGGAGCAGCACCTCCTAACTGGC CTGACCTGCAGTGGCCGCCAGGGAGGTCTGGGCCCAGCGGGGCTCCCTTCTGTGCAGACTTTTGGACCCAGCTCAGCACCAGCACCCGGG CGTCCTGAGCACTTTGCAAGAGAGATGGGCCCAAGGAATTCAGAAGAGCTTGCAGGCAAGCCAGGAGACCCTGGGAGCTGTGGCTGTCTT CTGTGGAGGAGGCTCCAGCATTCCCAAAGCTCTTAATTCTCCATAAAATGGGCTTTCCTCTGTCTGCCATCCTCAGAGTCTGGGGTGGGA GTGTGGACTTAGGAAAACAATATAAAGGACATCCTCATCATCACGGGGTGAAGGTCAGACTAAGGCAGCCTTCTTCACAGGCTGAGGGGG TTCAGAACCAGCCTGGCCAAAAATTACACCAGAGAGACAGAGTCCTCCCCATTGGGAACAGGGTGATTGAGGAAAGTGAACCTTGGGTGT GAGGGACCAATCCTGTGACCTCCCAGAACCATGGAAGCCAGGACGTCAGGCTGACCAACACCTCAGACCTTCTGAAGCAGCCCATTGCTG >97251_97251_2_USP18-DAPK2_USP18_chr22_18643035_ENST00000215794_DAPK2_chr15_64275953_ENST00000457488_length(amino acids)=424AA_BP=84 MSKAFGLLRQICQSILAESSQSPADLEEKKEEDSNMKREQPRERPRAWDYPHGLVGLHNIGQTCCLNSLIQVFVMNVDFTRILKSGQFAI VKKCREKSTGLEYAAKFIKKRQSRASRRGVSREEIEREVSILRQVLHHNVITLHDVYENRTDVVLILELVSGGELFDFLAQKESLSEEEA TSFIKQILDGVNYLHTKKIAHFDLKPENIMLLDKNIPIPHIKLIDFGLAHEIEDGVEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVI TYILLSGASPFLGDTKQETLANITAVSYDFDEEFFSQTSELAKDFIRKLLVKETRKRLTIQEALRHPWITPVDNQQAMVRRESVVNLENF -------------------------------------------------------------- >97251_97251_3_USP18-DAPK2_USP18_chr22_18643035_ENST00000215794_DAPK2_chr15_64275953_ENST00000558069_length(transcript)=2059nt_BP=684nt GACAGAATGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAGCGAGGGCTGGAAGTCTGGAGCAGGTGCGCGGCTGCAACGGCAGCC GCGGGAAGCTCGGGCCGGCAGGGTTTCCCCGCACGCTGGCGCCCAGCTCCCGGCGCGGAGGCCGCTGTAAGTTTCGCTTTCCATTCAGTG GAAAACGAAAGCTGGGCGGGGTGCCACGAGCGCGGGGCCAGACCAAGGCGGGCCCGGAGCGGAACTTCGGTCCCAGCTCGGTCCCCGGCT CAGTCCCGACGTGGAACTCAGCAGCGGAGGCTGGACGCTTGCATGGCGCTTGAGAGATTCCATCGTGCCTGGCTCACATAAGCGCTTCCT GGAAGTGAAGTCGTGCTGTCCTGAACGCGGGCCAGGCAGCTGCGGCCTGGGGGTTTTGGAGTGATCACGAATGAGCAAGGCGTTTGGGCT CCTGAGGCAAATCTGTCAGTCCATCCTGGCTGAGTCCTCGCAGTCCCCGGCAGATCTTGAAGAAAAGAAGGAAGAAGACAGCAACATGAA GAGAGAGCAGCCCAGAGAGCGTCCCAGGGCCTGGGACTACCCTCATGGCCTGGTTGGTTTACACAACATTGGACAGACCTGCTGCCTTAA CTCCTTGATTCAGGTGTTCGTAATGAATGTGGACTTCACCAGGATATTGAAGAGTGGCCAGTTTGCCATCGTGAAGAAGTGCCGGGAGAA GAGCACGGGGCTTGAGTATGCAGCCAAGTTCATCAAGAAGCGGCAGAGCCGGGCGAGCCGGCGCGGTGTGAGCCGGGAGGAGATCGAGCG GGAGGTGAGCATCCTGCGGCAGGTGCTGCACCACAATGTCATCACGCTGCACGACGTCTATGAGAACCGCACCGACGTGGTGCTCATCCT TGAGCTAGTGTCTGGAGGAGAGCTCTTCGATTTCCTGGCCCAGAAGGAGTCACTGAGTGAGGAGGAGGCCACCAGCTTCATTAAGCAGAT CCTGGATGGGGTGAACTACCTTCACACAAAGAAAATTGCTCACTTTGATCTCAAGCCAGAAAACATTATGTTGTTAGACAAGAATATTCC CATTCCACACATCAAGCTGATTGACTTTGGTCTGGCTCACGAAATAGAAGATGGAGTTGAATTTAAGAATATTTTTGGGACGCCGGAATT TGTTGCTCCAGAAATTGTGAACTACGAGCCCCTGGGTCTGGAGGCTGACATGTGGAGCATAGGCGTCATCACCTACATCCTCTTAAGTGG AGCATCCCCTTTCCTGGGAGACACGAAGCAGGAAACACTGGCAAATATCACAGCAGTGAGTTACGACTTTGATGAGGAATTCTTCAGCCA GACGAGCGAGCTGGCCAAGGACTTTATTCGGAAGCTTCTGGTTAAAGAGACCCGGAAACGGCTCACAATCCAAGAGGCTCTCAGACACCC CTGGATCACGTCAAAAGGAGAAGGCAGAGCCCCTGAACAGCGGAAGACAGAGCCCACCCAGCTGAAGACCAAGCACCTGAGAGAGTACAC TCTCAAATGCCACTCAAGCATGCCTCCCAACAACTCCTATGTCAACTTCGAGCGTTTTGCCTGTGTGGTGGAAGACGTGGCTCGGGTCGA CCTGGGATGCCGTGCCCTGGTGGAGGCCCACGATACCATCCAGGACGATGTGGAGGCCCTGGTCTCCATCTTCAATGAGAAGGAAGCTTG GTACCGAGAGGAGAATGAGAGCGCCCGGCATGACCTGTCCCAGCTCAGGTATGAGTTCCGCAAGGTGGAGTCATTGAAGAAGCTGCTGCG AGAAGACATCCAGGCCACGGGATGTAGCCTCGGAAGCATGGCCAGGAAACTGGACCATCTGCAAGCCCAGTTTGAGATTCTGAGGCAGGA GCTCTCCGCAGACCTGCAGTGGATTCAGGAGCTGGTGGGCAGCTTCCAGCTGGAGAGTGGGAGCTCTGAGGGCCTGGGCTCCACATTCTA >97251_97251_3_USP18-DAPK2_USP18_chr22_18643035_ENST00000215794_DAPK2_chr15_64275953_ENST00000558069_length(amino acids)=543AA_BP=84 MSKAFGLLRQICQSILAESSQSPADLEEKKEEDSNMKREQPRERPRAWDYPHGLVGLHNIGQTCCLNSLIQVFVMNVDFTRILKSGQFAI VKKCREKSTGLEYAAKFIKKRQSRASRRGVSREEIEREVSILRQVLHHNVITLHDVYENRTDVVLILELVSGGELFDFLAQKESLSEEEA TSFIKQILDGVNYLHTKKIAHFDLKPENIMLLDKNIPIPHIKLIDFGLAHEIEDGVEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVI TYILLSGASPFLGDTKQETLANITAVSYDFDEEFFSQTSELAKDFIRKLLVKETRKRLTIQEALRHPWITSKGEGRAPEQRKTEPTQLKT KHLREYTLKCHSSMPPNNSYVNFERFACVVEDVARVDLGCRALVEAHDTIQDDVEALVSIFNEKEAWYREENESARHDLSQLRYEFRKVE SLKKLLREDIQATGCSLGSMARKLDHLQAQFEILRQELSADLQWIQELVGSFQLESGSSEGLGSTFYQDTSESLSELLSRSCTEEFLAGW -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for USP18-DAPK2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for USP18-DAPK2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for USP18-DAPK2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies